GlassScriptPhysician profile
Joel T Johns
NPI 1043209703
$3,816.38
in general payments reported to CMS, 2019-2025
27 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $538 · 2021: $507 · 2022: $457 · 2023: $412 · 2024: $787 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $768.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $704.08 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $380.69 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $270.04 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $230.93 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $211.08 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $148.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $144.27 | 2019-2024 | |
| Irhythm Technologies, INC. | $123.87 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $91.05 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $83.41 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.26 | 2020-2021 | |
| Astellas Pharma US INC | $71.61 | 2019-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $66.71 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.88 | 2019-2024 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $59.50 | 2024-2025 | |
| Exact Sciences Corporation | $56.08 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $50.76 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $48.78 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $29.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.52 | 2022-2023 | Seglentis |
| Axsome Therapeutics, INC. | $23.78 | 2024 | Sunosi |
| Abbott Laboratories | $23.47 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $20.04 | 2022 | |
| Currax Pharmaceuticals LLC | $14.85 | 2021 | |
| Amarin Pharma, INC. | $13.54 | 2019 | |
| Eisai INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.